GNC names Philip Mallott to board
PITTSBURGH — GNC Holdings on Monday elected Philip Mallott to its board to fill the seat vacated by Norman Axelrod’s resignation.
Mallott served as VP and chief financial officer of Intimate Brands, a former subsidiary of Limited Brands, and most recently provided retail stock research as an independent consultant to Westminster Research Associates and, prior to that, as an analyst for Coker & Palmer. He is currently a director of Big Lots.
"We are excited that Phil has joined the GNC Board," stated Joseph Fortunato, president and CEO GNC. "His wealth of experience, particularly in the retail sector, should be an invaluable resource to GNC as we move forward."
Specialty Pharmacy Certification Board forms
WASHINGTON — A new organization aims to be an independent group to certify specialty pharmacists.
The National Association of Specialty Pharmacy and the Specialty Pharmacy Certification Board each formed as the result of a decision to create an independent certification board. Originally, the certification board would have been an entity within a professional organization granted autonomy in making decisions regarding certification.
The SPCB said it was developing "unique and differentiated" certifications for pharmacists, nurses and pharmacy technicians to respond to unmet needs that have arisen as specialty pharmacy has grown, noting that there currently are fewer than 15,000 pharmacists certified by two other certification boards out of the more than 275,000 licensed pharmacists in the United States.
Pfizer, J&J drug appears ineffective in some Alzheimer’s patients
NEW YORK — An experimental drug under development by Pfizer and a unit of Johnson & Johnson does not appear effective in Alzheimer’s disease patients who carry a certain genotype, according to results of a late-stage clinical trial announced by Pfizer on Tuesday.
The company said, however, that the phase-3 Study 302 of bapineuzumab in patients with mild-to-moderate Alzheimer’s — who carry the apolipoprotein E epsilon 4, or ApoE4 genotype — was the first of four, and a study of patients who do not carry the genotype was ongoing, along with two others of patients who do. Patients in Study 302 no longer will receive doses of the drug, Pfizer said, but will receive further evaluations later on.
Pfizer is developing the drug with J&J subsidiary Janssen AI under the Alzheimer’s Immunotherapy Program, which also includes three other studies that are ongoing: Study 301 of noncarriers of ApoE4 and two additional studies of carriers, Study 3001 and Study 3000.